A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenic Trial of Aripiprazole: (STAR) study;Wieloośrodkowe, randomizowane, naturalistyczne badanie otwarte arypiprazolu i opieki standardowej w leczeniu ambulatoryjnym pacjentów ze schizofrenia. Badanie STAR (Schizophrenia Trial of Aripiprazole)

Wiadomosci Psychiatryczne

Volumn 11, Issue 2, 2008, Pages 105-119

  Kerwin, Robert ^a   Millet, Bruno ^b   Herman, Erik ^c   Banki, Csaba M ^d   Lublin, Henrik ^e   Pans, Miranda ^f   Hanssens, Linda ^f   L'Italien, Gilbert ^f   McQuade, Robert D ^g   Beuzen, Jean Noël ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Regional Psychiatric Hospital   (Hungary)

^e Psychiatric Centre Glostrup   (Denmark)

^f BRISTOL MYERS SQUIBB   (United States)

^g OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Schizophrenia; Sripiprazole; Standard of care

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NATURALISTIC INQUIRY; OPEN STUDY; PARKINSONISM; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS; WEIGHT GAIN;

EID: 56349086577     PISSN: 15057429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003;160:1618-20.
2. Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877-93.
3. Bobes J, Canas F, Rejas J, Mackell J. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:1287-97.
4. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999;58(Suppl 1):I82-5.
5. Dossenbach M, Hodge A, Anders M, Molnar B, Peciukaitiene D, Krupka-Matuszczyk I, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005;8:195-201.
6. Dubisar BM, Stoner SC, Reynolds J, Khan R, Ramlatchman L. Adverse effects of atypical antipsychotic agents and their effects on quality of life. Pharmacotherapy 2004;24:843-7.
7. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27:263-72.
8. EuroQol Group. EuroQolda new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
9. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161:692-9.
10. Guy W. ECDEU assessment manual for psychopharmacology e revised. Rockville, MD: US Department of Health Services; 1976.
11. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-314.
12. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry 2005;162:2382-4.
13. Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
14. Jaffe AB, Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J Clin Psychiatry 2003;64:3-6.
15. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-17.
16. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102-11.
17. Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415-22.
18. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
19. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106-24.
20. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 2005;111:43-6.
21. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104.
22. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
23. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19:1-93.
24. NICE. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London, UK: National Institute for Clinical Excellence; 2002. Report No.: Technology Appraisal Guidance No. 43.
25. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000;321:483-4.
26. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8.
27. Peuskens J. Clinical effectiveness in adults with chronic schizophrenia. Eur Neuropsychopharmacol 2004; 14(Suppl 4):S453-9.
28. Pigott TA, Carson WH, Saba AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
29. Ritsner M, Perelroyzen G, Ilan H, Gibel A. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24:245-54.
30. Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004;65:547-50.
31. Sebastian CS, Glazer W, Buckley PF. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 2004;11:329-42.
32. Stein E. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler Suppl 2002;2:19-23. discussion -5.
33. Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005;136: 211-21.
34. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77-89.
35. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59:1147-54.
36. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
37. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl 18):13-26.